- Home
- NLSP
as 06-06-2025 4:00pm EST
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
| Founded: | 2015 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 423.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $18.39 | Next Earning Date: | 06-17-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NLS Pharmaceutics Ltd. News
NLSP Breaking Stock News: Dive into NLSP Ticker-Specific Updates for Smart Investing
PR Newswire
17 days ago
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
MT Newswires
2 months ago
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder
PR Newswire
2 months ago
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
ACCESS Newswire
2 months ago
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
PR Newswire
3 months ago
NLS Pharmaceutics CEO Issues Letter to Shareholders
PR Newswire
3 months ago
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
PR Newswire
3 months ago
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
PR Newswire
4 months ago
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
Compare NLSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NLSP NLS Pharmaceutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.